Immunomedics Inc
IMMU
IMMU was delisted on the 22nd of October, 2020.
205 hedge funds and large institutions have $2.3B invested in Immunomedics Inc in 2018 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 80 increasing their positions, 60 reducing their positions, and 42 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 60
2% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 42
1% less funds holding
Funds holding: 207 → 205 (-2)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
25% less capital invested
Capital invested by funds: $3.08B → $2.3B (-$782M)
28% less call options, than puts
Call options by funds: $99.5M | Put options by funds: $138M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.1M |
| 2 |
Millennium Management
New York
|
+$32.9M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$31.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$23.1M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$32.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$17.3M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$16.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$15.3M |
| 5 |
Alkeon Capital Management
New York
|
-$13.6M |
IMMU Hedge Fund Activity: Q4 2018 in Review
205 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q4 2018, worth a combined $2.3B — down 25% from $3.08B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new IMMU positions and 42 closed out — a net gain of 1 holder — while 80 added to existing stakes and 60 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was Acuta Capital Partners, cutting an estimated $32.9M.
- 205 institutional investors held Immunomedics Inc (IMMU) as of Q4 2018, down from 207 in Q3 2018.
- Funds reported $2.3B of Immunomedics Inc stock for Q4 2018, down 25% quarter-over-quarter.
- 43 funds opened new Immunomedics Inc positions in Q4 2018 and 42 closed out, a net change of +1 holder.
- The largest Immunomedics Inc buyer in Q4 2018 was Fidelity Investments, an estimated $53.1M added.
- The largest Immunomedics Inc seller in Q4 2018 was Acuta Capital Partners, an estimated $32.9M sold.
Based on aggregated 13F filings for Q4 2018.